Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity

Chimeric human immunodeficiency virus type 1 (HIV-1) molecular clones differing only in the envelope V3 region were constructed. The V3 regions were derived from two HIV-1 isolates with a non-syncytium-inducing, non-T-cell-tropic phenotype and from four HIV-1 isolates with a syncytium-inducing, T-cell-tropic phenotype. When assayed in SupT1 cells, the two chimeric viruses with a V3 region derived from the non-syncytium-inducing isolates did not induce syncytia and showed a low level of replication. The four chimeric viruses with a V3 region derived from the syncytium-inducing isolates did induce syncytia and replicated efficiently in SupT1 cells. In A3.01 cells, which do not support syncytium formation, the V3 loop affected replication similarly. Upon prolonged culture in SupT1 cells, the phenotype of a non-syncytium-inducing, low-replicating chimeric HIV-1 converted into a syncytium-inducing, high-replicating phenotype. Mutations within the usually conserved GPGR tip of the loop, which were shown to be responsible for the conversion into the syncytium-inducing, high-replicating phenotype, had occurred. In vitro mutagenesis showed that coupled changes of amino acids at both sides of the tip of the V3 loop were able to convert the viral phenotype from non-syncytium-inducing, low replicating into syncytium inducing, high replicating. Our data show that the V3 loop is involved in both syncytium forming and replicative capacity of HIV-1.

[1]  P. Earl,et al.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity , 1988, Journal of virology.

[2]  M. Akutsu,et al.  Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene , 1991, Journal of virology.

[3]  L. van der Hoek,et al.  Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. , 1991, Virology.

[4]  M. Emerman,et al.  Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding , 1989, Journal of virology.

[5]  S. Matsushita,et al.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope , 1988, Journal of virology.

[6]  A J Langlois,et al.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[7]  L. Arthur,et al.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Peter D. Kwong,et al.  Crystal structure of an HIV-binding recombinant fragment of human CD4 , 1990, Nature.

[9]  W. Blattner,et al.  C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals. , 1990, AIDS research and human retroviruses.

[10]  A J Langlois,et al.  Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.

[12]  G. Nakamura,et al.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor , 1987, Cell.

[13]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[14]  J. Goudsmit,et al.  Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. , 1988, The Journal of infectious diseases.

[15]  Q. Sattentau,et al.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.

[16]  R. Schooley,et al.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins , 1987, Journal of virology.

[17]  C. Debouck,et al.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Sodroski,et al.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.

[19]  B. Seed,et al.  A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site , 1990, Cell.

[20]  M. Reitz,et al.  Envelope sequences of two new United States HIV-1 isolates. , 1988, Virology.

[21]  E. Freed,et al.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain , 1991, Journal of virology.

[22]  J. Berzofsky,et al.  Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. , 1991, Journal of immunology.

[23]  R. Weiss,et al.  Neutralizing monoclonal antibodies to the AIDS virus. , 1988, AIDS.

[24]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[25]  Lange,et al.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates , 1989, Journal of virology.

[26]  J. Davide,et al.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.

[27]  W. O'brien,et al.  HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain , 1990, Nature.

[28]  L. Callahan,et al.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions , 1991, Journal of virology.

[29]  M. Gurney,et al.  Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. , 1988, Science.

[30]  S. Matsushita,et al.  Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. , 1990, Journal of immunology.

[31]  A. Profy,et al.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.

[32]  C. DeLisi,et al.  An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Salimans,et al.  RapidandSimple MethodforPurification ofNucleic Acids , 1990 .

[34]  G. Shaw,et al.  Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. , 1984, Science.

[35]  R. Redfield,et al.  Type-restricted neutralization of molecular clones of human immunodeficiency virus. , 1988, Science.